TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Multiple myeloma (MM) is an incurable plasma cell malignancy.
• Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinase (MAPK) pathways are crucial for MM drug resistance.
• Transforming growth factor-β activated kinase 1 (MAP3K7, TAK1) regulates NF-κB and MAPK signaling.

Purpose of the Study:

• To investigate TAK1 as a potential therapeutic target in multiple myeloma.
• To evaluate the efficacy of TAK1 inhibitors NG25 and 5Z-7-oxozeaenol (5Z-7) in MM models.
• To assess the impact of TAK1 inhibition on MM cell growth, drug resistance, and myeloma bone disease.

Main Methods:

• Analysis of MAP3K7 expression in relation to patient survival.
• Cytotoxicity assays of TAK1 inhibitors (NG25, 5Z-7) on MM cell lines and patient cells.
• Assessment of gene expression changes (MYC, E2F) and signaling pathway activation (NF-κB, MAPK, p38, JNK) upon treatment.
• Evaluation of TAK1 inhibitor effects on osteoclast differentiation and viability.

Main Results:

• High MAP3K7 expression correlated with shorter overall and progression-free survival in MM patients.
• TAK1 inhibitors NG25 and 5Z-7 demonstrated significant cytotoxicity against MM cells.
• NG25 treatment reduced expression of MYC and E2F controlled genes, impacting tumor cell growth and drug resilience.
• Combined treatment with melphalan and TAK1 inhibitors showed synergistic or additive cytotoxicity.
• TAK1 inhibition reduced osteoclast differentiation and viability, mitigating bone degradation.

Conclusions:

• TAK1 is a promising drug target for multiple myeloma treatment.
• TAK1 inhibition offers a dual therapeutic strategy by targeting cancer cells and reducing myeloma bone disease.
• Further investigation of TAK1 inhibitors in MM is warranted.